ChitogenX Gestione

Gestione criteri di controllo 2/4

ChitogenX Il CEO è Pierre Laurin, nominato in Feb2024, ha un mandato di meno di un anno. possiede direttamente 3.13% delle azioni della società, per un valore di CA$ 13.03K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.2 anni e 5.4 anni.

Informazioni chiave

Pierre Laurin

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	3.1%
Durata media del management	6.2yrs
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Pierre Laurin (63 yo)

less than a year

Mandato

Mr. Pierre Laurin, B.Sc.Pharm. M.Sc. serves as Chairman of ChitogenX Inc. since July 21, 2022 and serves as its Interim CEO since February 28, 2024. He serves as Director at ChitogenX Inc. (formerly known...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Pierre Laurin	Interim CEO & Chairman	less than a year	Nessun dato	3.13% CA$ 13.0k
Luc Mainville	Senior VP & CFO	6.2yrs	CA$187.18k	5.19% CA$ 21.6k
Guy-Paul Allard	VP of Legal Affairs & Corporate Secretary	8.4yrs	Nessun dato	1.48% CA$ 6.2k
Jonathan Sackier	Senior Vice President of Medical Affairs	2.5yrs	CA$280.27k	0.76% CA$ 3.2k
Frédéric Dumais	Director of Communications & Investor Relations	no data	Nessun dato	Nessun dato
Benedek Simo	Controller	6.2yrs	Nessun dato	Nessun dato

6.2yrs

Durata media

Gestione esperta: Il team dirigenziale di CHGX è esperto e expertise (durata media dell'incarico 6.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Pierre Laurin	Interim CEO & Chairman	5.4yrs	Nessun dato	3.13% CA$ 13.0k
Jack Farr	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Steven Saviuk	Director	9.8yrs	Nessun dato	0.10% CA$ 436.3
Timothy Cunningham	Independent Director	3.4yrs	Nessun dato	Nessun dato
Scott Rodeo	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Patrick O'Donnell	Independent Director	3.8yrs	Nessun dato	Nessun dato
Brent Norton	Director	8.3yrs	Nessun dato	1.83% CA$ 7.6k
Martyn Snow	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Caroline Hoemann	Member of Scientific Advisory Board	no data	Nessun dato	4.35% CA$ 18.1k
Jacques Toueg	Member of Clinical Advisory Board	6.7yrs	Nessun dato	Nessun dato
Howard Walthall	Independent Director	3.4yrs	Nessun dato	Nessun dato

5.4yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CHGX sono considerati esperti (durata media dell'incarico 5.4 anni).

ChitogenX Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Less than half of directors are independent

ChitogenX Inc., Annual General Meeting, Jul 19, 2023

High number of new directors

High number of new directors

President exercised options to buy CA$106k worth of stock.

Recent updates

Insufficient new directors

New major risk - Revenue and earnings growth

Chitogenx Inc. Demonstrates ORTHO-R Efficacy and Osteoarthritidevelopment in Large Animal Study

New major risk - Financial position

Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Less than half of directors are independent

New major risk - Share price stability

ChitogenX Inc., Annual General Meeting, Jul 19, 2023

ChitogenX Inc. announced that it has received CAD 3.856348 million in funding

ChitogenX Inc. Demonstrates Ortho-R Residency Properties in Meniscus Study

ChitogenX Inc. announced that it expects to receive CAD 6.1 million in funding

Chitogenx Successfully Completes Initial Portion of Its U.S. Phase I/Ii Rotator Cuff Repair Clinical Trial

ChitogenX Inc. Launches Second Orthopedic Development Program in Meniscus Repair

High number of new directors

Ortho Regenerative Technologies Inc. Announces Enrollment of First Patient in Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Ortho Regenerative Technologies Inc. Initiates Patients Recruitment for its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial

Ortho Regenerative Technologies Receives Key U.S. Composition and Method Patent for Ortho-R Soft Tissue Repair Platform

High number of new directors

Ortho Regenerative Technologies Inc. announced that it has received CAD 3.2 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 3 million in funding

Ortho Regenerative Technologies Inc. Announces U.S. IND Clinical Hold Lifted by the FDA & Clearance to Proceed with U.S. Clinical Trial

Ortho Regenerative Technologies Announces Extension of FDA Clinical Hold of ORTHO-R Investigational New Drug Application

Ortho Regenerative Technologies Inc. Receives Clinical Hold Letter from the U.S. Food and Drug Administration

Forecast to breakeven in 2026

New 90-day low: CA$0.54

President exercised options to buy CA$106k worth of stock.

Ortho Regenerative Technologies Inc. Announces Board Changes

Ortho Regenerative Technologies Inc. Enters into Global Licensing Agreement with Hanuman Pelican Inc

Ortho Regenerative Technologies Inc. announced that it has received CAD 3 million in funding from Leede Jones Gable Inc.

New 90-day high: CA$0.74

Ortho Regenerative Technologies Inc. Announces Appointment of Mukesh Ahuja as Vice-President Clinical and Medical Affairs, Effective November 1, 2020

Ortho Regenerative Technologies Inc. announced that it has received CAD 0.1376 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 0.2 million in funding

New 90-day high - CA$0.43

Ortho Regenerative Technologies Inc. announced that it has received CAD 2.47482 million in funding

Ortho Regenerative Technologies Inc. announced that it expects to receive CAD 0.64 million in funding

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media